Compare Franco-Nevada Corporation (FNV) vs 10X Genomics Inc (TXG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Franco-Nevada Corporation vs 10X Genomics Inc — how do they compare? Franco-Nevada Corporation trades at $238.3 (market cap $45.36B), while 10X Genomics Inc trades at $70.24 (market cap $9.53B). The key difference: Franco-Nevada Corporation is far larger — about 4.8× 10X Genomics Inc's market cap, and Franco-Nevada Corporation pays a 0.75% dividend while 10X Genomics Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Franco-Nevada Corporation for 0 Days and 10X Genomics Inc for 91 Days on average.
| FNV | TXG | |
|---|---|---|
Market Cap | $45.36B | $9.53B |
Volume | 787,841 | 4,138,224 |
Sector | Basic Materials | Health |
52-Week High | $280.82 | $97.74 |
52-Week Low | $183.97 | $11.83 |
Typical Hold Time | 0 Days | 91 Days |
Enterprise Value | $44.34B | $9.05B |
Dividend Yield | 0.75% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Franco-Nevada (FNV) trades at $243.85, showing a slight decline of 0.77% over the past day. The stock is positioned neutrally from a technical perspective, with key support near $242 and resistance at $246. Fundamentally, the company exhibits strong profitability with a net income margin of 63.79% and has beaten earnings expectations in two of the last three quarters. Recent news highlights portfolio expansion, including a significant investment in the Bullabulling Gold Project and positive developments regarding the potential restart of the Cobre Panama mine.
The outlook for FNV is supported by analyst consensus, with a price target of $275 suggesting potential upside. Key opportunities include revenue growth from new projects and high profit margins. Risks involve execution on new investments, commodity price volatility, and geopolitical factors affecting mining operations. The balanced analyst rating split indicates cautious optimism for future performance.
TXG trades at $71.79, down 4.52% on the day, amid a bearish technical signal. The company shows improving fundamentals with revenue of $642.82M in 2025 and a narrowing net loss of -$43.54M. Recent news highlights strong demand for its Atera spatial biology platform and a patent victory, though insider selling and high valuation ratios like a P/S of 15.13 and EV/EBITDA of 241.6 present concerns.
The outlook is mixed; analyst consensus is a Buy with a $83.30 price target, but execution risks on Atera delivery and sustained profitability remain key. Upside depends on commercial success of new platforms, while downside risks include competitive pressures and failure to achieve positive earnings.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Franco-Nevada Corporation
Franco-Nevada Corporation is a royalty and streaming company that finances mining and energy projects in exchange for royalty payments or the right to purchase output at set prices, holding a diversified portfolio across Precious Metals, Other Mining, and Energy (oil, gas, and natural gas liquids).
Read more on FNV →About 10X Genomics Inc
10x Genomics Inc is a life science technology company based in the United States. Its solutions include instruments, consumables, and software for analyzing biological systems. The product portfolio of the company includes Chromium Controller, Reagent Kits, 10x Compatible Products, and Informatics Software among others. The majority of its revenue is generated from consumables.
Read more on TXG →
